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ttention deficit/hyperactivity disorder (ADHD)
is the most common psychiatric disorder of childhood.In
recent years there has been growing evidence that in many
patients the disorder persists into adulthood.Meanwhile,
adult ADHD has been recognized in the literature as a
valid clinical entity, affecting as many as 2% to 4% of
adults.
1
Symptomatology and diagnosis
The core symptoms of ADHD are inattention,hyperac-
tivity,and impulsivity.
2 In most descriptions of ADHD in
the 1980s and the early 1990s,it seemed that hyperactiv-
ity had to be present in every case as a striking symptom,
but with growing knowledge of ADHD it became evi-
dent that not all patients–in particular girls–present
hyperactivity.Since 1994,with the fourth edition of the
Diagnostic and Statistical Manual of Mental Disorders
(DSM IV)
3 three types of ADHD have been differenti-
ated:
• Combined type (6 or more symptoms of hyperactiv-
ity/impulsivity as well as of inattention);
• Inattentive type (6 or more symptoms of inattention);
• Hyperactive/impulsive type (6 or more symptoms of
hyperactivity/impulsivity).
A change in symptoms with increasing age is character-
istic of ADHD. After puberty, hyperactivity often
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The persistence of attention deficit hyperactivity disor-
der (ADHD) into adolescence and adulthood has now
been accepted as a clinical entity. The rate of prevalence
among adults is assumed to be from 2% to 4%. With
increasing age, a symptom change has to be considered;
disturbance of attention becomes more prominent,
whereas hyperactivity often diminishes or changes to
inactivity. Neuroimaging studies show a high striatal
dopamine transporter (DAT) availability in most adults
with ADHD; this can be reduced by stimulants. Nicotine
seems to have a stimulant-like action on the DAT. In most
adults with ADHD, therapy has to be multimodal, com-
bining psychotherapy and medication. Methylphenidate
is the first-line drug in adult ADHD; further options are
amphetamine and noradrenaline reuptake inhibitors.
Nonresponders to methylphenidate seem to have no ele-
vated DAT availability prior to therapy. Combination
with other psychiatric disorders occurs frequently in
adults with ADHD; in these patients additional pharma-
cological treatment with special regard to the comorbid
disease is recommended.     
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:39-36.changes to inactivity; therefore, ADHD often is not
accepted as a diagnosis in adults.Impulsivity normally
lessens with age. Adults with ADHD seem to have a
problem with willpower:activity can be overexerted,but
if a task is not attractive to the person, this results in a
lack of effort. Or, inattention can change to hyperfo-
cussing,when the person is attracted by a task.
With adults,differing patterns of comorbidity and symp-
tom heterogeneity pose new conceptual,diagnostic,and
treatment challenges. While core symptoms are often
overt problems in children, in adults subtler executive
dysfunction appears.Even though the growing consen-
sus is that ADHD is a disorder of executive functions
(EF), the details of the EF/ADHD connection remain
unclear and may be far more complex in adults.
4
In Table I examples are given for the changes of the 18
DSM-IV symptoms from childhood to adulthood.The 6-
question Adult Self-Report Scale – V 1.1 (ASRS - V 1.1)
Screener (http://www.hcp.med.harvard.edu/ncs/fpdir/adhd)
is a subset of the WHO's 18-question Adult Self-Report
Scale – V 1.1 (ASRS - V 1.1) Symptom Checklist. The
patient should fill in checkmarks. Four or more check-
marks in the darkly shaded areas may indicate that the
symptoms are consistent with adult ADHD (Figure 1).
Wender developed a set of characteristics to specify both
childhood criteria and current ADHD symptoms.
5 He
pointed out affective lability,which is not mentioned in
DSM-IV,as a frequent symptom in adult ADHD.
Prevalence of ADHD in adulthood
The prevalence of ADHD in children according to DSM-
IV criteria varies from 2.4% to 19.8%.
6 Concerning per-
sistence into adulthood,most authors describe a rate of
about 50%.The largest follow-up study, which investi-
gated 197 Chinese children after 15 years,showed a rate
of persistence of 70%.
7,8 Generally,the degree of preva-
lence (1% to 6% in adults) depends on the view of the
reporter in the initial assessment.Most instruments con-
sist of some form of self-report, and in adulthood it is
often not possible to ask information of parents or per-
sons with a close relationship to the patient.Patients with
ADHD are often not aware of their symptoms,or do not
report the severity of symptoms.
Neurobiological basis of ADHD
Current interest in the neurobiological basis of ADHD
originally commenced in the 1970s.Neurochemical,neu-
rophysiological,and radiological attributes were noted,
proving,in particular,abnormalities in the dopaminergic
and noradrenergic system.Genetic investigations showed
increased evidence that genetic components were pre-
sent in most cases of ADHD, which is now seen as the
psychiatric disease with the highest heritability.
9
Neuroimaging studies with magnetic resonance imaging
(MRI),photon-emission tomography (PET),and single
photon-emission computed tomography (SPECT) sug-
gest involvement of striatal structures in ADHD.
10-13
Molecular genetic studies described an involvement of a
polymorphism of the dopamine transporter (DAT) 1
gene in ADHD (eg,a higher rate of homozygosity of the
10-repeat allele in the 3´untranslated region of exon 15
of the DAT gene on chromosome 5p15.3).
14-19
With regard to the suspected striatal impairment in
ADHD and the known effect of methylphenidate on the
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Selected abbreviations and acronyms
ADHD attention deficit hyperactivity disorder
DAT dopamine transporter
MRI magnetic resonance imaging
PET photon-emission tomography
SPECT single photon-emission computed tomography
Figure 1. Adult Self-Report Scale (ASRS) Screener: 4 or more check-
marks in the shaded areas may indicate symptoms of adult
ADHD. ADHD, attention deficit hyperactivity disorder.
ASRS 6 Questions
Never
Rarely
Sometimes
Often
Very often
1.How often do you have trouble 
   wrapping up the final details of a 
   project, once the challenging 
   parts have been done?
2.How often do you have difficulty 
   getting things in order when you 
   have to do a task that requires 
   organization?
3.How often do you have problems 
   remembering appointments or 
   obligations?
4.When you have a task that requires 
   a lot of thought, how often do you 
   avoid or delay getting started?
5.How often do you fidget or squirm 
   with your hands or your feet when 
   you have to sit down for a long time?
6.How often do you feel overly active 
   and compelled to do things, like you 
   were driven by a motor?DAT mainly localized in this section of the brain,since the
end of the 1990s DAT has been investigated in patients
with ADHD. This is carried out by using radioactive
marked ligands which are known to bind effectively with
the DAT system.A group of investigators from Boston
used altropane marked with iodine-123
20;our group from
Munich and Philadelphia used the cocaine derivative
TRODAT-1 marked with technetium 99m.
21 Both studies
showed a clearly higher availability of DAT in the striatum
of adult patients with ADHD compared with the normal
healthy controls.
20-23While DAT availability was found to
be raised to 17% in the investigations using TRODAT-1
compared with the control collective (Figure 2),the group
using altropane demonstrated a rise of 70% in 6 patients;
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Table I. Comparison of ADHD symptoms in adulthood according to ASRS (http://www.med.nyu.edu/psych/assets/adhdscreen18.pdf.) in the left col-
umn and in childhood according to DSM-IV
3 in the right column. ADHD, attention deficit hyperactivity disorder.
1. How often do you have trouble wrapping up the final details of
a project, once the challenging parts have been done?
2. How often do you have difficulty getting things in order when 
you have to do a task that requires organization?
3. How often do you have problems remembering appointments 
or obligations?
4. When you have a task that requires a lot of thought, how often 
do you avoid or delay getting started?
5. How often do you fidget or squirm with your hands or feet 
when you have to sit down for a long time?
6. How often do you feel overly active and compelled to do things, 
like you were driven by a motor?
7. How often do you make careless mistakes when you have to 
work on a boring or difficult project?
8. How often do you have difficulty keeping your attention when 
you are doing boring or repetitive work?
9. How often do you have difficulty concentrating on what people 
say to you, even when they are speaking to you directly?
10. How often do you misplace or have difficulty finding things at 
home or at work?
11. How often are you distracted by activity or noise around you?
12. How often do you leave your seat in meetings or other 
situations in which you are expected to remain seated?
13. How often do you feel restless or fidgety?
14. How often do you have difficulty unwinding and relaxing 
when you have time to yourself?
15. How often do you find yourself talking too much when you 
are in social situations?
16. When you’re in a conversation, how often do you find yourself 
finishing the sentences of the people you are talking to, before 
they can finish them themselves?
17. How often do you have difficulty waiting your turn in situations 
when turn taking is required?
18. How often do you interrupt others when they are busy?
Often does not follow through on instructions and fails to finish 
schoolwork, chores, or duties in the workplace (and due to 
oppositional behavior or failure to understand instructions)
Often has difficulty organizing tasks and activities
Is often forgetful in daily activities
Often avoids, dislikes, or is reluctant to engage in tasks that require 
sustained mental effort (such as schoolwork or homework)
Often fidgets with hands or feet or squirms in seat 
Is often "on the go" or often acts as if "driven by a motor" 
Often fails to give close attention to details or makes careless 
mistakes in schoolwork, work, or other activities 
Often has difficulty sustaining attention in tasks or play activities 
Often does not seem to listen when spoken to directly 
Often loses things necessary for tasks or activities (eg, toys, 
school assignments, pencils, books, or tools)
Is often easily distracted by extraneous stimuli 
Often leaves seat in classroom or in other situations in which 
remaining seated is expected 
Often runs about or climbs excessively in situations in which it is 
inappropriate (in adolescents or adults, may be limited to subjective 
feelings of restlessness)
Often has difficulty playing or engaging in leisure activities quietly
Often talks excessively
Often blurts out answers before questions have been completed
Often has difficulty awaiting turn
Often interrupts or intrudes on others (eg, butts into conversations 
or games)this percentage was reduced to around 30% in a larger
group of 19 patients on continuation of the altropane
study (Spencer T,personal communication).Meanwhile,a
rise in DAT availability was also detected in the basal gan-
glia of children with ADHD by means of an [
123I] N-(3-
iodopropen-2-yl)-2-carbo-methoxy-3β-(4-chlorphenyl)
tropane (IPT)-SPECT investigation,
24 following initial
results with N-ω-fluoropropyl-2 β-carboxymethoxy-3 β-{4-
iodophenyl} tropane (FP-CIT).
25 Interestingly,a rise in the
DAT could not be detected in a SPECT investigation with
β-CIT
26;this could be due to the extremely slow kinetics of
β-CIT (measurement 1 day after application) or another
specificity of this radiotracer,which also binds with sero-
tonin transporters and possibly holds other substructures
of DAT compared with altropane,FP-CIT,IPT,or TRO-
DAT-1.Our own initial results revealed that the DAT was
raised not only in the hyperactive-impulsive and combined
type,but also in the inattentive type of ADHD (Figure 3).
It may be deduced from a neurochemical view that with
an increase in DAT,which transports dopamine back from
the synaptic cleft,less dopamine is available in the synap-
tic cleft of dopamine-dependent neurons. The results
obtained by our group showed not only the impairment of
DAT but also reported for the first time in vivo and
intraindividually in patients with ADHD, that impaired
metabolism can be improved with methylphenidate: on
administration of 5 mg 3 times daily it was seen that there
was a clear reduction in DAT availability in all patients
after a period of 4 weeks (Figure 2).
22,23With this very low
dose, most of these patients demonstrated a lower con-
centration of DAT than did the control group.In a study
involving six children with ADHD,an IPT-SPECT inves-
tigation confirmed a marked reduction in DAT density
under administration of methylphenidate.
27 Regarding
normal healthy individuals, other authors were able to
show evidence of a similar reduction in DAT under
methylphenidate in a PET investigation with [C-11]
cocaine.
28 In conclusion,the SPECT investigations on DAT
confirmed the supposition that with ADHD an impair-
ment is present mainly in the dopaminergic system.This
can be improved with the introduction of stimulants.Our
initial results show that nonresponders to methylphenidate
do not reveal raised DAT in striatum prior to therapy,
whereas the responders seem to have a high DAT avail-
ability (Figure 4).
29
Clinical research
32
Figure 2. DAT availability in striatum, measured with TRODAT-1 SPECT,
in 17 adults with ADHD before and after (in 16 patients) 4
weeks of intake of 5 mg methylphenidate 3 times daily, com-
pared with 16 controls, and in relation to age. DAT, dopamine
transporter; SPECT, single photon emission computed tomog-
raphy; ADHD, attention deficit hyperactivity disorder.
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Figure 3. DAT availability in the striatum of smoking and nonsmoking
adults with ADHD with only inattentive symptoms since child-
hood and with hyperactivity/impulsivity in the childhood,
mostly in combination with attention deficit and in non-
smoking controls, shown by specific accumulation of [Tc-
99m]TRODAT-1 in SPECT scans, in the age groups of 20 to 40
years and over 40 years. DAT, dopamine transporter; ADHD,
attention deficit hyperactivity disorder; SPECT, single photon
emission computed tomography; STR, specific binding in stria-
tum; BKG, specific binding in the cerebellum as background.
Reproduced from reference 12: Krause KH, Dresel SH, Krause J, la
Fougere C, Ackenheil M. The dopamine transporter and neuroimag-
ing in attention deficit hyperactivity disorder. Neurosci Biobehav Rev.
2003;27:605-613. Copyright © Elsevier 2003.
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ControlsIt should be noted,for possible diagnostic applications of
SPECT, that the DAT concentration decreases with
increase of age
30 and that nicotine may influence DAT
availability.
12 The lowering of DAT with increasing age
may be an explanation for our observation, that most
adults need lower doses of methylphenidate compared
with children and adolescents.Nicotine seems to have a
similar effect on the DAT as do stimulants (Figure 3).
Investigating potential reasons for the lower elevation in
the TRODAT-1 study compared with the altropane study,
we found a subgroup of patients with relatively little
increase in DAT despite severe clinical impairments;fur-
ther questioning of these patients revealed that all of them
were cigarette smokers.Comparison of 11 smoking non-
medicated patients with ADHD with sex- and age-
matched nonsmoking drug-naive adults with ADHD
showed significantly higher DAT density in the nonsmok-
ing patients,despite higher ADHD scores for the smok-
ers.
31This finding suggests that nicotine may act directly on
DAT in the same manner as stimulants.In a self-trial,DAT
availability was reduced by over 50% 5 hours after intake
of 20 mg methylphenidate in a slow-release formulation;
wearing a nicotine skin patch,equaling 10 to 20 cigarettes
daily,for 5 hours.In the same subject 3 months later,an
effect similar to that of methylphenidate was seen (Figure
5),confirming the view that the lowering of DAT after use
of nicotine is not a sign of a neurochemical adaptation
associated with chronic exposure to nicotine.
12 Further evi-
dence comes from the reevaluation of a woman with
ADHD,who was smoking 15 cigarettes per day at the time
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Figure 4. Specific binding of striatal DAT, measured with [99mTc]TRO-
DAT-1 SPECT in 18 adults with ADHD (percentage of devia-
tion from values of controls of the same age) in relation to
CGI values after 10 weeks of intake of methylphenidate. DAT,
dopamine transporter; SPECT, single photon emission com-
puted tomography; ADHD, attention deficit hyperactivity dis-
order.
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Figure 5. DAT availability in the striatum of a 53-year-old nonsmoker
before (A), after 5 hours of intake of 20 mg methylphenidate
(Ritalin SR
®) (B), and 3 months later after 5 hours of wearing
a 17.5 mg/24 h nicotine skin patch (C), shown by specific
accumulation of [Tc-99m]TRODAT-1 in SPECT scans. DAT,
dopamine transporter; SPECT, single photon emission com-
puted tomography; STR, specific binding in striatum; BKG,
specific binding in the cerebellum as background.
Reproduced from reference 12: Krause KH, Dresel SH, Krause J, la
Fougere C, Ackenheil M. The dopamine transporter and neuroimag-
ing in attention deficit hyperactivity disorder. Neurosci Biobehav Rev.
2003;27:605-613. Copyright © Elsevier 2003.
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Transversal
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Figure 6. DAT availability in the striatum of a 29-year-old female smoker
with ADHD before (A), after 4 weeks of intake of 3x5 mg
methylphenidate (Ritalin
®) per day (B), and 2 years later after
1 year of cessation of nicotine abuse and intake of
methylphenidate, shown by specific accumulation of [Tc-
99m]TRODAT-1 in SPECT scans. DAT, dopamine transporter;
ADHD, attention deficit hyperactivity disorder; SPECT, single
photon emission computed tomography; STR, specific bind-
ing in striatum; BKG, specific binding in the cerebellum as
background.
Reproduced from reference 12: Krause KH, Dresel SH, Krause J, la
Fougere C, Ackenheil M. The dopamine transporter and neuroimag-
ing in attention deficit hyperactivity disorder. Neurosci Biobehav Rev.
2003;27:605-613. Copyright © Elsevier 2003.
Striatal DAT density
([STR-BKG]/BKG=1.28)
in a 28-year-old woman
with ADHD without
medication, smoking 15
cigarettes per day
Transversal
Lowering of DAT density
([STR-BKG]/BKG=0.96)
in the same woman
4 weeks after commencing
treatment with 3x5 mg
methylphenidate/d
Transversal
Increase in DAT density
([STR-BKG]/BKG=1.52)
2.5 years later after 
stopping smoking as well 
as intake of stimulants
for aver a year
Transversalof first investigation with TRODAT-1,showing no remark-
able elevation of DAT; 4 weeks of intake of 3x5 mg
methylphenidate led to a marked reduction similar to the
other patients in this group. One year later, the patient
stopped the nicotine and methylphenidate intake;2 years
after the first investigation she returned with increased
complaints of ADHD.At this time she underwent another
TRODAT-1 SPECT scan,presenting with a 19% elevation
compared with the first scan with nicotine and a 61% ele-
vation compared with the second scan with nicotine and
methylphenidate (Figure 6).This finding is in accordance
with the opinion that the effect of nicotine on DAT does
not result in a persistent loss of DAT.
32 In this context,it is
of interest that an investigation with [
123I]β-CIT SPECT
showed no altered striatal uptake in smokers versus con-
trols,
33 a potential parallel to the above mentioned findings
of no DAT elevation in ADHD with this method.
Treatment of adults
Most patients need multimodal therapy:psychoeducation
concerning the special aspects of ADHD is essential.
Many patients have problems with their self-esteem due
to a misunderstanding of the symptoms and a childhood
with parents suffering from ADHD–especially impulsiv-
ity–and they need additional psychotherapy.
Treatment with stimulants is the drug therapy of first
choice
34 and is approved in the USA for adults (d-
methylphenidate and amphetamines); stimulants for
adult ADHD are as effective as in children.An investi-
gation performed in the year 2000 in Germany showed
that only 0.024‰ of the adults registered in the public
health system—that is 90% of the adult population—was
treated with methylphenidate in Germany at this time
(Figure 7).
35That is about one out of 40 000 and includes
all kinds of treatments, including for narcolepsy and
other psychiatric diseases.
In the treatment of adults with ADHD we start with a
daily dose of 5 mg,reaching 15 mg methylphenidate after
14 days of treatment.Titration up to 40 mg follows,if the
patient needs more than the initial end point of the 15-
mg dose.But more than 70% of our patients did not tol-
erate doses above 30 mg without having marked side
effects.Frequently,they felt an increased inner tension.
With higher doses,they also described a state resembling
the impairments they experienced before the treatment.
Most of them had a good stabilization with a combina-
tion of methylphenidate in a dose up to 20 mg and addi-
tional antidepressants.
With all patients we try to start monotherapy with stimu-
lants. When methylphenidate has no positive effect on
depressive or other comorbid symptoms,we start an addi-
tional medication after 4 weeks of treatment. Some
patients do not tolerate methylphenidate well;they feel
more depressed after starting the methylphenidate med-
ication,but they are not as inattentive as before the begin-
ning of therapy; in this situation we change from
methylphenidate to amphetamines; some patients have
more benefits from this kind of stimulants acting in dual
ways.When selecting the additional medication it is impor-
tant to regard the comorbid disorder. We experienced
good clinical response with the following medication:
• Depression:venlafaxine 18.75-150 mg/d
• Depression combined with severe distraction:amisul-
pride 25 – 100 mg/d
• OCD:sertraline 50-100 mg/d
• Borderline syndrome:venlafaxine 37.5 mg -150 mg/d
• Slight autistic symptoms:fluoxetine 10-20 mg/d
The use of tricyclic antidepressants is problematic,as the
long-term effect is not as good as that of treatment with
new antidepressants.The change seems to take place after
3 months.The side effects often lead to treatment dropouts.
In recent years the norepinephrine reuptake inhibitor
atomoxetine was introduced as an additional possibility
to treat ADHD.
36This substance does not influence the
dopamine in the striatum,but in the prefrontal cortex,
where dopamine transport is mediated by norepineph-
rine transporter.
37 ❏
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Figure 7. Percentage of patients treated with methylphenidate in rela-
tion to age in the years 1998 (N=65 412), 1999 (N=64 701)
and 2000 (N=63 115) in a German district.
Reproduced from reference 35: Ferber L v, Lehmkuhl G, Köster I, et al.
Methylphenidatgebrauch in Deutschland: Versichertenbezogene epi-
demiologische Studie über die Entwicklung von 1998 bis 2000. Dtsch
Ärztebl. 2003;100:A41-46. Copyright © Deutsches Arzeblatt 2003
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Trastorno de hiperactividad con déficit de
atención de adolescentes y adultos, con
especial énfasis en el transportador de la
dopamina y en la nicotina
Hoy, se acepta que el trastorno de hiperactividad
con déficit de atención (THDA) puede persistir
como entidad clínica hasta la adolescencia y vida
adulta. La tasa de prevalencia entre los adultos
varía entre el 2% y el 4%. Con el envejecimiento se
produce un cambio sintomático; el trastorno de
atención se agudiza, mientras que la hiperactividad
suele disminuir o se torna en inactividad. Los estu-
dios de neuroimagen revelan una gran disponibili-
dad del transportador de dopamina del estriado
(DAT) entre la mayoría de los adultos con THDA; los
estimulantes reducen su concentración. Al parecer,
la nicotina estimula el DAT. El tratamiento de la
mayoría de los adultos con THDA es multimodal —
combinación de psicoterapia y medicación. El metil-
fenidato es el fármaco preferido para el THDA del
adulto; otras posibilidades son la anfetamina y los
inhibidores de la recaptación de noradrenalina. Al
parecer, las personas que no responden al metilfe-
nidato no muestran una disponibilidad elevada de
DAT antes del tratamiento. Los adultos con THDA
suelen padecer otros trastornos psiquiátricos; se
recomienda un tratamiento farmacológico adicio-
nal de estos pacientes, prestando especial atención
a la enfermedad asociada.
Hyperactivité et déficit de l’attention
(HADA) à l’adolescence et à l’âge adulte :
mise au point sur le transporteur de la 
dopamine et la nicotine
La persistance d’un trouble d’hyperactivité et d’un
déficit de l’attention à l’adolescence et à l’âge
adulte (HADA) est maintenant acceptée en tant
qu’entité clinique. La prévalence chez les adultes est
estimée entre 2 et 4 %. Il faut tenir compte des
symptômes qui se modifient avec l’âge : le trouble
de l’attention s’aggrave alors que souvent l’hype-
ractivité diminue ou se mue en inactivité. Les étu-
des de neuro-imagerie montrent une présence
striatale élevée du transporteur de la dopamine
(TD) chez la plupart des adultes atteints de HADA,
qui peut être diminuée par des stimulants. La nico-
tine semble avoir la même action sur le TD que les
stimulants. Chez la plupart des adultes souffrant de
HADA, le traitement doit être multimodal, asso-
ciant psychothérapie et médicaments. Le méthylp-
hénidate est le traitement de première intention
chez l’adulte souffrant de HADA ; les autres choix
sont les amphétamines et les inhibiteurs de la
recapture de la noradrénaline. Le taux de TD avant
le traitement ne semble pas élevé chez les non-
répondeurs au méthylphénidate. D’autres troubles
psychiatriques sont souvent associés au HADA chez
l’adulte ; chez ces patients il est recommandé de
traiter le trouble comorbide.
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